Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Moors & Cabot Inc.

Moors & Cabot Inc. lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,134 shares of the pharmaceutical company’s stock after selling 1,363 shares during the period. Moors & Cabot Inc.’s holdings in Vertex Pharmaceuticals were worth $1,840,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of VRTX. Activest Wealth Management acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Access Investment Management LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $27,000. Flaharty Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth $32,000. Finally, American National Bank & Trust boosted its stake in Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.1%

Shares of VRTX opened at $417.00 on Thursday. The company has a 50-day simple moving average of $403.70 and a 200-day simple moving average of $430.56. The company has a market capitalization of $106.92 billion, a PE ratio of 29.81 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $4.38 EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of several recent analyst reports. Cantor Fitzgerald reduced their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Tuesday. HC Wainwright reduced their target price on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a research note on Tuesday, August 5th. Raymond James Financial initiated coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. Finally, BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $489.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.